Literature DB >> 6359906

Evaluation of promastigote and amastigote antigens in the indirect fluorescent antibody test for American cutaneous leishmaniasis.

M G Pappas, P B McGreevy, R Hajkowski, L D Hendricks, C N Oster, W T Hockmeyer.   

Abstract

Leishmania braziliensis panamensis promastigotes, temperature-induced in vitro-cultivated amastigotes, Vero cell-derived amastigotes, and rodent lesion-derived amastigotes were evaluated as antigens in the indirect immunofluorescent antibody (IFA) test for American cutaneous leishmaniasis. Test sensitivity was determined using sera from 34 U.S. soldiers with leishmaniasis diagnosed by demonstrating parasites in their skin lesions. Sera were collected from 3 to 24 months after exposure to Leishmania. Positive IFA reactions among patient sera were 82% with promastigotes or lesion amastigotes, 79% with in vitro amastigotes, and 76% with Vero cell amastigotes (P = N.S.). Positive titers ranged from 1:8 to 1:128 using all antigens. Test specificity was determined with 30 sera from healthy individuals. False positive reactions ranged from 0-5% depending on the antigen and all titers were less than or equal to 1:8. Test cross-reactivity was assessed with 47 sera from patients with other diseases. Depending on the antigen, cross-reactions occurred with sera from patients with Chagas' disease, lupus erythematosus, malaria, toxoplasmosis and amebiasis. None of the antigens cross-reacted with sera from patients with viral hepatitis, coccidioidomycosis, syphilis, schistosomiasis, and trichinosis. In replicate experiments, 99-100% of the sera varied no more than +/- 1 titer dilution. As sensitivity, specificity, cross-reactivity, and reproducibility of the four antigens were statistically similar, promastigotes, which can be easily and economically cultured in large numbers in vitro are recommended for use in the IFA test for American cutaneous leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6359906     DOI: 10.4269/ajtmh.1983.32.1260

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  4 in total

1.  Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses.

Authors:  E Nascimento; W Mayrink; C A da Costa; M S Michalick; M N Melo; G C Barros; M Dias; C M Antunes; M S Lima; D C Taboada
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

2.  Evaluation of serological diagnostic indices for mucocutaneous leishmaniasis: immunofluorescence tests and enzyme-linked immunoassays for IgG, IgM and IgA antibodies.

Authors:  M C Guimarães; B J Celeste; E L Franco; L C Cucé; W Belda
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

3.  Identification of an immunodominant 32-kilodalton membrane protein of Leishmania donovani infantum promastigotes suitable for specific diagnosis of Mediterranean visceral leishmaniasis.

Authors:  F Tebourski; A el Gaied; H Louzir; R Ben Ismail; R Kammoun; K Dellagi
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

4.  Detection of IgG Anti-Leishmania Antigen by Flow Cytometry as a Diagnostic Test for Cutaneous Leishmaniasis.

Authors:  Geraldo Pedral-Sampaio; Jessé S Alves; Albert Schriefer; Andréa Magalhães; Roberto Meyer; Marshall J Glesby; Edgar M Carvalho; Lucas P Carvalho
Journal:  PLoS One       Date:  2016-09-13       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.